OSI Pharmaceuticals Announces Conference Call on ODAC Review of Tarceva® for Use as First-line Maintenance Therapy in Advanc...

OSI Pharmaceuticals, Inc. (Nasdaq:OSIP) announced today that the Company will host a live conference call Thursday, December 17, at 8:30 AM Eastern Time to discuss the Oncologic Drug Advisory Committee (ODAC) panel’s review of the supplemental New Drug Application (sNDA) for use of Tarceva® (erlotinib) as first-line maintenance therapy for patients with advanced or metastatic non-small cell lung cancer whose cancer has not progressed following first-line treatment with platinum-based chemotherapy.

To access the live call or the seven-day archive via the Internet, log on to www.osip.com. Please connect to the Company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call 1-877-879-6174 (U.S.) or 1-719-325-4758 (international) to listen to the call. The conference ID number for the live call is 7991541. Telephone replay is available approximately two hours after the call through December 31, 2009. To access the replay, please call 1-888-203-1112 (U.S.) or 1-719-457-0820 (international) and reference ID number 7991541.

About OSI Pharmaceuticals

OSI Pharmaceuticals is committed to "shaping medicine and changing lives" by discovering, developing and commercializing high-quality, novel and differentiated targeted medicines designed to extend life and improve the quality of life for patients with cancer and diabetes/obesity. For additional information about OSI, please visit http://www.osip.com.

This news release contains forward-looking statements. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a difference include, among others, OSI's and its collaborators' abilities to effectively market and sell Tarceva and to expand the approved indications for Tarceva, OSI’s ability to protect its intellectual property rights, safety concerns regarding Tarceva, competition to Tarceva and OSI’s drug candidates from other biotechnology and pharmaceutical companies, the completion of clinical trials, the effects of FDA and other governmental regulation, including pricing controls, OSI's ability to successfully develop and commercialize drug candidates, and other factors described in OSI Pharmaceuticals' filings with the Securities and Exchange Commission.